Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment
- 19 July 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (11), 2630-2637
- https://doi.org/10.1080/10428194.2020.1783443
Abstract
A cross-sectional online survey, including a discrete choice experiment (DCE), was used to investigate first-line treatment preferences in patients with classical Hodgkin lymphoma (cHL) in the United States; 141 patients (median age 35.0 years) participated. In the DCE, risk of progression at 2 years (progression free survival) had the highest relative importance to patients (31.3%) when considering first-line treatments, followed by 2-year overall survival (OS; 26.9%), on-treatment pulmonary toxicity (23.3%), and on-treatment peripheral neuropathy (18.5%). Marginal rate of substitution analyses demonstrated that a 0.44% and 0.09% increase in 2-year OS was required for patients to accept a 1% increase in the risk of disease progression at 2 years and peripheral neuropathy, respectively. A 2.6% increase in 2-year OS was needed to accept a 7% rather than a 2% risk of pulmonary toxicity. In summary, patients with cHL rated survival attributes as more important than drug-related toxicity when considering first-line treatments.This publication has 30 references indexed in Scilit:
- The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?Blood, 2018
- Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and managementAmerican Journal of Hematology, 2018
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s LymphomaThe New England Journal of Medicine, 2018
- Current strategies for salvage treatment for relapsed classical Hodgkin lymphomaTherapeutic Advances in Hematology, 2017
- Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort StudyThe Lancet Oncology, 2016
- Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalatedPlus Four Cycles of BEACOPPbaselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup TrialJournal of Clinical Oncology, 2016
- ABVD or BEACOPP for Advanced Hodgkin LymphomaJournal of Clinical Oncology, 2016
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)Journal of Clinical Oncology, 2013
- State-of-the-art Issues in Hodgkin’s Lymphoma SurvivorshipCurrent Oncology Reports, 2010
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 StudyJournal of Clinical Oncology, 2009